In January 2023, the smart contact lens died in public. Mojo Vision, the
Saratoga startup that had raised $205 million to build a display the size of a
grain of sand and float it on your eyeball, laid off three-quarters of its
staff and put the lens “on hold.” CEO Drew Perkins blamed the slumping economy,
tight capital markets, and a market for advanced augmented reality that was, in
his words, yet to be proven. The press wrote the obituary. TechCrunch, Axios,
and a dozen XR blogs filed the same story: the most famous AR contact lens on
Earth was finished, and the company would pivot to selling microLED parts to
headset makers instead.

The patents did not get the memo.

Pull the US grant record for contact lenses that carry a working display, a
projector, or a microLED array, and the line does not crater after 2023. It
holds. The patent office issued 12 such grants in 2023, 15 in 2024, and 13
through the first half of 2025, with 25 distinct companies and universities
filing in the category since 2019. The single largest holder is a Cupertino
company called Tectus Corporation, which owns 125 US grants. Tectus is not a
competitor to Mojo Vision. Tectus is Mojo Vision. The lens that Silicon
Valley buried is still being patented, week after week, by the same people who
were supposed to have given up on it. They just stopped issuing press releases
and started cashing defense checks.

The display that wouldn’t fit anywhere else

To understand why nobody could kill this thing, you have to look at what is
actually inside the lens, because it is genuinely hard to build and there is
nothing else quite like it.

The hardest part is the screen. A contact lens display has to be smaller than
the pupil it sits over, which means a working color screen measured in
hundreds of microns. Mojo’s 2022 demo unit packed roughly 14,000 pixels per
inch into a green monochrome display the size of a sand grain. By 2024 the
company was claiming sub-micron LEDs and densities up to 28,000 pixels per inch,
the highest-density displays anyone has built. One recently granted Tectus
patent describes an LED array where the top surfaces of adjacent emitters are
separated by no more than half a micron, using ruthenium mirrors under each
diode to claw back light that would otherwise leak sideways, and packs at least
a 200-by-200 grid of color pixels into the footprint. Another claims a
quantum-dot color-conversion layer stacked directly over blue gallium-nitride
microLEDs, the same trick Samsung and BOE are fighting over for living-room
televisions, shrunk to fit on a cornea.

This is the engineering DNA that connects the whole category. Delete the phrase
“contact lens” from every patent in the set and you are still looking at the
same problem: cram a sub-micron-pitch emissive display, a CMOS driver backplane,
a wireless power-and-data link, and an eye-tracking sensor into a soft polymer
disc that rides on living tissue and cannot get warm. These patents do not share
a buzzword. They share a manufacturing process. That is the difference between a
label and a technology.

The detour through the eye socket

Here is where the story stops being a comeback and starts being something
stranger. Read the most recent Tectus grants and a second use for the display
appears, one that has nothing to do with consumer AR.

A patent issued in January 2025 describes an “intraocular femtoprojector,” a
microLED projector small enough to be surgically implanted inside the eye. The
claims spell out the purpose: when the device is placed in a patient with a
damaged fovea, the central pit of the retina that does most of your seeing, the
projector is aimed to throw its image onto retina away from the dead spot. A
companion patent, “Restoring sight after corneal blindness,” pairs a scleral
contact lens carrying a tiny camera, a “femtoimager,” with the implanted
projector and camera-equipped eyeglasses. The lens tracks where your eye points,
the glasses capture the world, and the implant paints the relevant slice of that
image directly onto whatever healthy retina you have left. Multiple projectors,
the patent notes, can be made redundant or tuned to different colors and fields
of view, and one variant carries a sensor to read the pressure inside the eye.

The consumer AR display and the blindness implant are the same silicon. The
company that could not find a market selling you a heads-up display for your
commute is using the identical microLED to build an artificial fovea for people
who have lost theirs. This is the adjacent possible at work: a technology
developed for one job, declared commercially dead, sitting one recombination
away from a completely different job in a completely different industry. The
sand-grain screen did not get worse when the AR market cooled. It went looking
for a patient instead of a customer.

Who is paying for the funeral

Follow the money and the revival has two backers, neither of them the consumer
electronics buyers everyone assumed the lens needed.

The first is the US military. Tectus holds Air Force SBIR contracts, run
through the AFWERX program, to adapt its AR lens for use by the Air Force, with
the stated goals of integrating the military’s Android Team Awareness Kit
mapping software, running on-eye trials, and pursuing FDA clearance for field
use. A soldier with a display on his eyeball and no visible hardware is a
procurement officer’s idea of a good time. The economics that did not work for
a $799 consumer gadget work fine when the customer is a defense program of
record with a multi-year budget.

The second backer is in Dubai. In July 2025, a deep-tech startup called
XPANCEO raised a $250 million Series A at a $1.35 billion valuation, becoming,
by TechFundingNews’s count, the United Arab Emirates’ twelfth unicorn. The
round, led by Opportunity Venture, brought its total to $290 million, serious
money for a product that does not yet exist. XPANCEO says it is building a
single lens that does AR display, continuous glaucoma monitoring, and night
vision at once, with clinical trials promised for late 2026. It is the same
convergence Mojo chased, funded by Gulf capital that does not flinch at a
decade-long bet. A third company, the Washington-state outfit Innovega, keeps
filing too, patenting see-through display panels and mixed-reality eyewear with a
deformable beam combiner, its long-running scheme to split the optical load
between a lens and a pair of glasses.

The fifteen-year fuse

None of this is new. It is just finally lit.

The whole field traces to a single lab. Around 2008, Babak Parviz and Brian
Otis, then on the electrical-engineering faculty at the University of
Washington, built the first contact lens with a wirelessly powered LED and,
soon after, a glucose sensor that read sugar in tears. A graduate student named
Claire Yao made the original prototype on National Science Foundation money.
Their 2011 paper on a 3-microwatt CMOS glucose sensor for a contact lens has
been cited more than 360 times. Parviz and Otis carried the idea to Google,
which announced its glucose-sensing “smart contact lens” in January 2014 with
Novartis, then shelved it by 2018 when the tear-glucose correlation proved too
noisy to trust. A 2018 paper cited more than 600 times finally put a working
LED display and a glucose sensor into a soft lens transparent enough to see
through and tested it in a live animal eye, proving the full stack could coexist
on the cornea.

Parviz is now a vice president at Amazon. The glucose lens that started it all
is dead. The display lens that grew out of it was pronounced dead in 2023. And
yet the patents keep landing at a rate of more than a dozen a year, the Air
Force is funding on-eye trials, a billion-dollar Dubai startup is promising
clinics by next year, and the same microLED is quietly becoming an implant for
the blind.

For an R&D director or a corporate scout, the signal is not that the AR contact
lens is back. It is who revived it. When a consumer category fails, the default
assumption is that the technology was premature and the patents are dead weight.
This category says the opposite: the technology was fine, the customer was
wrong. The buyer was never going to be a commuter wanting notifications. It was
a defense program that needs an invisible display and a surgeon who needs a new
fovea. The lens did not need a better chip. It needed a different checkbook.

Method note. Patent counts come from a corpus of 9.3 million US utility
grants sourced from USPTO bulk grant data, current through early June 2026,
searched by full text for contact lenses combined with display, projector, or
microLED terms; assignee counts combine variant spellings and subsidiary
filings. Grant dates lag patent filing by two to three years, so 2024 and 2025
grants reflect work done early this decade. Citation counts and publication years
come from OpenAlex, a database of about 357 million scholarly works. Funding
figures, display densities, and defense-contract details are drawn from the cited
reporting and the patents’ own claims; XPANCEO’s product is pre-clinical and its
described capabilities are company claims, not verified performance. No claim is
made about the safety, efficacy, or medical outcomes of any device.